Abeona Therapeutics Inc (ABEO)
NASDAQ:ABEO
Want to see ABEO full AI Analyst Report?
Top Page
Abeona Therapeutics
(NASDAQ:ABEO)
Select Model
Select Model
Rating:56Neutral
Price Target:
$5.50
▲(0.00% Upside)
Action:Reiterated
Date:06/13/26
The score is held back primarily by persistent operating losses and heavy ongoing cash burn despite improving revenue and solid gross margins. Offsetting these risks are a relatively manageable leverage profile, early commercial momentum and favorable payer coverage discussed on the earnings call, and a low P/E that is tempered by concerns about earnings quality.
Positive Factors
Early commercial revenue traction
Sustained commercial receipts from ZEVASKYN demonstrate initial product-market fit and a nascent, recurring revenue stream tied to treatments. Early monetization reduces binary clinical-stage risk and supports reinvestment in sales, manufacturing and targeted rollout over the next 2–6 months.
Negative Factors
Large negative operating and free cash flow
Material cash burn indicates the business is reliant on external financing to sustain operations and scale commercial activities. Persistent negative operating cash flow constrains runway, increases dilution risk from future financings, and limits self-funded expansion absent sustained revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Early commercial revenue traction
Sustained commercial receipts from ZEVASKYN demonstrate initial product-market fit and a nascent, recurring revenue stream tied to treatments. Early monetization reduces binary clinical-stage risk and supports reinvestment in sales, manufacturing and targeted rollout over the next 2–6 months.
Read all positive factors
Abeona Therapeutics (ABEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$315.18M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)4.7
Beta (1Y)1.54
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.28
Shares Outstanding56,995,144
10 Day Avg. Volume830,551
30 Day Avg. Volume1,081,695
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue20.03
Enterprise Value/Gross Profit38.57
Enterprise Value/Ebitda3.97
Forecast
1Y Price Target
$19.20Price Target Upside249.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$66.29M
Abeona Therapeutics Business Overview & Revenue Model
Company Description
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corr...
How the Company Makes Money
Abeona Therapeutics does not have consistently disclosed, product-based commercial revenue as a primary earnings source; as a clinical-stage biotech, it has historically funded operations mainly through financing activities (e.g., equity offerings...
Abeona Therapeutics Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call presents clear early commercial momentum for ZEVASKYN (notable revenue acceleration, 95% published commercial coverage, growing QTC network and manufacturing success with no harvest failures) and meaningful pipeline advancement with the in-licensed PSMA SIR-T program. Offsetting these positives are elevated operating expenses (notably SG&A), a larger reported net loss driven partly by a $7M upfront license payment, a declining cash balance, and operational / payer timing risks (variable biopsy lead times and lengthy insurance approvals for out-of-state Medicaid). On balance, the positives — strong initial revenue growth, payer coverage, successful manufacturing outcomes and a targeted oncology asset with limited near-term spend — outweigh the near-term financial and operational challenges.Positive Updates
Early Commercial Revenue Traction
Net product revenue of $8.7M in Q1 2026 driven by three commercially insured patients treated in the quarter, up $6.3M vs. $2.4M in Q4 2025 (≈+262.5% quarter-over-quarter).
Negative Updates
Increased Net Loss
Net loss of $17.1M ($0.30 per share) in Q1 2026 versus $12.0M ($0.24 per share) in Q1 2025, an increase of $5.1M (≈+42.5%), primarily reflecting commercial investment and the $7M PSMA licensing transaction.
Read all updates
Q1-2026 Updates
Positive
Negative
Early Commercial Revenue Traction
Net product revenue of $8.7M in Q1 2026 driven by three commercially insured patients treated in the quarter, up $6.3M vs. $2.4M in Q4 2025 (≈+262.5% quarter-over-quarter).
Read all positive updates
Company Guidance
Management's guidance focused on near‑term launch cadence and measured pipeline spend: Q1 product revenue was $8.7M from three commercial treatments (five patients treated since the Dec‑2025 launch), with one patient treated so far this quarter, one in manufacturing and six additional patients expected to be biopsied this quarter (four already scheduled) — manufacturing turnaround ~23–24 days (observed 23–26 days) — and several of these could fall into Q2; the company has six active QTCs, is targeting seven QTCs in 2026 (with a longer‑term target of ~9–10 centers) and expects steady‑state throughput of roughly one patient/month per QTC, a near‑term identified pool of >100 patients and active engagement with 45 physicians, with payer coverage published for 95% of commercially covered lives and an anticipated payer mix of ~60% commercial / ~30–33% Medicaid. Financial guidance: cost of sales in Q1 was $2.7M, R&D $9.6M (including a $7M upfront PSMA license payment), SG&A $19.5M, net loss $17.1M ($0.30/share), cash and short‑term investments $168.3M (vs. $191.4M YE2025); management expects gross‑to‑net in the mid–to‑upper teens as volumes normalize, minimal PSMA R&D this year (low single‑digit millions), a pre‑IND meeting June 3, 2026 and IND/first‑in‑human studies targeted in H2 2027, and stated monthly profitability could be achievable as early as June depending on biopsy/treatment cadence.Abeona Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.54M | 5.82M | 0.00 | 3.50M | 1.41M | 3.00M |
| Gross Profit | 7.55M | 4.29M | -2.91M | 1.90M | 964.00K | 3.00M |
| EBITDA | 73.43M | 78.59M | -56.62M | -50.57M | -34.38M | -76.82M |
| Net Income | 66.14M | 71.18M | -63.73M | -54.19M | -39.70M | -84.94M |
Balance Sheet | ||||||
| Total Assets | 198.49M | 219.57M | 108.93M | 64.00M | 64.21M | 79.59M |
| Cash, Cash Equivalents and Short-Term Investments | 168.27M | 191.40M | 97.72M | 52.23M | 52.15M | 45.02M |
| Total Debt | 23.17M | 24.97M | 23.05M | 5.40M | 7.63M | 9.38M |
| Total Liabilities | 53.55M | 60.35M | 64.90M | 49.18M | 37.45M | 37.22M |
| Stockholders Equity | 144.94M | 159.22M | 44.03M | 14.83M | 26.76M | 42.37M |
Cash Flow | ||||||
| Free Cash Flow | -85.24M | -84.30M | -58.46M | -37.34M | -43.61M | -69.82M |
| Operating Cash Flow | -77.73M | -76.33M | -56.02M | -37.01M | -43.48M | -65.67M |
| Investing Cash Flow | 105.78M | 105.03M | -39.24M | 208.00K | -23.96M | 66.06M |
| Financing Cash Flow | 17.05M | 26.04M | 104.14M | 37.06M | 43.17M | 24.86M |
Abeona Therapeutics Technical Analysis
Positive
5.50
Price Trends
5.46
Positive
5.20
Positive
5.26
Positive
Market Momentum
<0.01
Positive
50.22
Neutral
33.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABEO, the sentiment is Positive. The current price of 5.5 is below the 20-day moving average (MA) of 5.53, above the 50-day MA of 5.46, and above the 200-day MA of 5.26, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.22 is Neutral, neither overbought nor oversold. The STOCH value of 33.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABEO.
Abeona Therapeutics Risk Analysis
Abeona Therapeutics disclosed 48 risk factors in its most recent earnings report. Abeona Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Abeona Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $315.18M | 4.73 | 41.40% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $315.53M | -3.71 | -107.19% | ― | ― | ― | |
49 Neutral | $239.78M | -2.14 | -2781.56% | ― | 289.94% | 16.60% | |
46 Neutral | $763.48M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
41 Neutral | $171.89M | -6.69 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
ABEO
Abeona Therapeutics
5.53
-0.63
-10.23%
GALT
Galectin Therapeutics
2.67
1.30
94.89%
SLN
Silence Therapeutics
6.69
1.36
25.52%
HUMA
Humacyte
1.06
-1.32
-55.49%
VOR
Vor Biopharma
14.36
10.72
294.51%
Abeona Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Abeona Shareholders Back Board, Equity Plan at Meeting
Positive
Jun 12, 2026
At its virtual annual meeting on June 12, 2026, Abeona Therapeutics stockholders elected Keith A. Goldan and Bernhardt G. Zeiher, M.D. as Class 1 directors to serve until the 2029 annual meeting, and approved on an advisory basis the compensation ...
Executive/Board Changes
Abeona Therapeutics announces resignation of board member
Neutral
Jun 12, 2026
On June 11, 2026, Abeona Therapeutics Inc. announced that Board member Michael Amoroso resigned from the company’s Board of Directors, effective immediately, and also stepped down from the Nominating and Corporate Governance Committee. The c...
Business Operations and StrategyRegulatory Filings and Compliance
Abeona Therapeutics Updates Investor Presentation Under Regulation FD
Neutral
Jun 10, 2026
On an unspecified recent date, Abeona Therapeutics Inc. furnished an updated investor presentation in a Current Report on Form 8-K for use in meetings with investors, analysts, and other market participants. The materials were provided as a furnis...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Abeona Advances ABO-701 T-Cell Therapy Toward IND
Positive
Jun 4, 2026
On June 3, 2026, Abeona Therapeutics Inc. held a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration to discuss ABO-701, its recently licensed engineered T-cell therapy targeting Prostate-Specific Membrane Antigen for t...
Business Operations and StrategyExecutive/Board Changes
Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair
Positive
Apr 7, 2026
On April 7, 2026, Abeona Therapeutics announced that Keith A. Goldan had been appointed as an independent member of its Board of Directors, effective April 1, 2026, and as Chairman of the Audit Committee. With more than two decades of financial le...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
Neutral
Mar 20, 2026
On March 16, 2026, Abeona Therapeutics Inc.’s board approved Third Amended and Restated Bylaws, replacing bylaws last updated on July 9, 2024, to clarify rules around calling, postponing, rescheduling, or canceling annual and special shareho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.